Beren Therapeutics is a private late-stage rare-disease biotechnology company developing precision therapies for ultra-rare genetic disorders, with a lead program approaching an FDA filing. The company leverages patient-specific genetic insights to develop targeted small-molecule and antisense therapies.
Company Info
Funding & Investor Relations
Pre-IPO; considering public offering following FDA decision in 2027.
Upcoming Milestones & Key Dates
FDA NDA submission for BER-101 lead rare disease program
Anticipated FDA decision (PDUFA) on BER-101
Clinical Development Pipeline
Recent News
Beren Therapeutics added $300M in new financing as it prepares for an FDA decision on its lead rare-disease therapy, giving the company a multi-year commercial runway and capacity for a potential launch next year.
Beren Therapeutics has added $300M in fresh financing as it approaches an FDA filing for its lead rare-disease program, bringing the company's total private capital raise to over half a billion dollars.
Leadership Team
Careers & Job Openings